Asset 1

Discovery Life Sciences COVID-19 Statement

To our Valued Patients, Customers, Partners and Suppliers:

Discovery Life Sciences is closely monitoring the coronavirus (COVID-19) outbreak to take every immediate and prudent action possible to provide for the protection and safety of our patients, employees, customers, partners and suppliers. The current uncertainty of the COVID-19 outbreak is highly disruptive and is presenting many challenges, but we are prepared and continue to work with all constituents to anticipate and mitigate any new developments, while continuing to serve your needs as a global market leader in biospecimen, genomic, cell and immunohistochemistry services. We value our relationship with you and have implemented the necessary scientific processes and business practices as part of a robust business continuity plan to specifically address the environment created by these events.

We are adhering to all pertinent guidance from the United States Center for Disease Control and Prevention (CDC), and the World Health Organization (WHO), and can confirm our commitment to provide for the safety of the clinical, scientific, academic and industry communities we serve around the world, while continuing to support the advancement of medical research and minimize the disruption of that important work. At this time, we do not expect delays in delivery of the services we provide. We continue to urge all of our clients to diligently follow all of the appropriate precautions when handling human biospecimens.

Please contact your Discovery Life Sciences representative or our headquarters office at for any additional information.

We look forward to the opportunity to better serve you. All of our lines of communication will remain open throughout the term of this event.

Thank you for your continued support. As always, we are Science at your Service.

Very Sincerely,
Glenn Bilawsky
Chief Executive Officer
Discovery Life Sciences

Quick Links


Development and Clinical
Trial Solutions